“The still maturing median PFS we are seeing of over 9 months for PD-1 naive 1L r/m HNSCC, compares favorably with the 3.2 month median PFS reported for Keytruda monotherapy in the KN-048 study”— Rom S. Leidner, MD.
UbiVac is Pioneering the World's 1st Dark Matter Cancer Immunotherapy
UbiVac's DPV-001 Dark Matter combo Immunotherapy triples response rate and progression-free survival (PFS) over PD-1 alone for patients with r/m head and neck cancer. Data were presented at the Society for Immunotherapy of Cancer Annual Meeting November 7-10, 2024, in Houston, TX.
ASCO 2024 Dark Matter Interview with Dr. Bernard Fox American Society of Clinical Oncology, Dark Matter Interview, ASCO. June 1, 2024
An Off-the-Shelf Multivalent Vaccine Containing Cancer’s Dark Matter, DPV-001, Combined with PD-1 +/- GITR in Head & Neck Cancer: Safety, Efficacy, and Immunodynamics from the Phase 1 GITRVax Trial. These data will be presented by Rom S. Leidner, M.D., during the First-in-Human Phase I Clinical Trials Session 1 on April 8 (No. CT112, Poster Section 48, 1:30 to 5pm), at the American Association for Cancer Research Annual Meeting held 5-10 April in San Diego, CA. https://www.einpresswire.com/article/701519390/dpv-001-vaccine-containing-cancer-s-dark-matter-yields-2-to-3-fold-increased-response-rate-for-head-and-neck-cancer